Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC)
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: BIOLOGICAL: Camrelizumab|DRUG: Nab paclitaxel|DRUG: Epirubicin|DRUG: Cyclophosphamide
Sponsor: Shandong Cancer Hospital and Institute
Collaborators: Jiangsu HengRui Medicine Co., Ltd.